8月21日，云顶新耀盘中下跌6.77%，报31.34港元，成交额1874.68万港元。此前一个交易日，受莫德纳与默沙东mRNA个性化癌症疫苗三期临床取得阳性结果及公司中期业绩大超预期双重催化，该股盘中一度飙升近89%，收涨41.43%。今日开盘即出现明显回落，市场资金获利了结意愿较强。
基本面上，公司上半年收益11.48亿元，同比增长157%，Non-IFRS净利润9723万元实现扭亏为盈，核心产品耐赋康贡献超77%营收。同板块康希诺生物同日跌3.31%，mRNA概念股整体呈现冲高回落态势。
云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司，已建立跨肾病、抗感染及自身免疫性疾病的产品管线。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.